Table 5.

Subgroup analysis of the association between hyperuricemia and adverse outcomes.

Factors	Subgroup	HR (95% CI)	Interaction P-value
Age	<65 years	2.396 (0.865–6.582)	0.677
	≥65 years	1.769 (0.673–4.648)
Sex	Male	2.963 (1.055–8.327)	0.412
	Female	1.624 (0.571–4.609)
Hypertension	Yes	1.026 (0.379–2.773)	0.048
	No	4.314 (1.564–11.906)
Diabetes	Yes	1.646 (0.275–9.863)	0.784
	No	2.155 (1.008–4.603)
Smoking	Yes	3.238 (0.913–11.481)	0.408
	No	1.741 (0.731–4.152)
Atrial fibrillation	Yes	0.431 (0.045–4.145)	0.137
	No	2.538 (1.208–5.335)
Hyperlipidaemia	Yes	0.503 (0.052–4.839)	0.175
	No	2.596 (1.230–5.435)
LVEF	<50	2.147 (0.744–6.191)	0.636
	≥50	1.519 (0.570–4.049)
eGFR	<60	2.784 (0.591–13.119)	0.488
	≥60	1.466 (0.574–3.747)

BMI, body mass index; LVEF, left ventricular ejection fraction; eGFR, estimated Glomerular filtration rate; HR, hazard ratio; CI, confidence interval.